Parallel Advisors’s Axsome Therapeutics AXSM Stock Holding History

Parallel Advisors’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.87K	Buy	17 +2	+13%	+$345	﹤0.01%	3249
2025 Q4	$2.74K	Buy	15 +3	+25%	+$419	﹤0.01%	3048
2025 Q3	$1.46K	Hold	12	–	–	﹤0.01%	3129
2025 Q2	$1.25K	Sell	12 -3	-20%	-$318	﹤0.01%	3150
2025 Q1	$1.75K	Buy	15 +3	+25%	+$342	﹤0.01%	3010
2024 Q4	$1.01K	Hold	12	–	–	﹤0.01%	3108
2024 Q3	$1.08K	Hold	12	–	–	﹤0.01%	3014
2024 Q2	$966	Buy	+12	New	+$888	﹤0.01%	2967
2022 Q1	–	Sell	-92	Closed	-$3K	–	2967
2021 Q4	$3K	Buy	92 +15	+19%	+$552	﹤0.01%	2551
2021 Q3	$3K	Buy	77 +60	+353%	+$2.34K	﹤0.01%	2541
2021 Q2	$1K	Hold	17	–	–	﹤0.01%	2691
2021 Q1	$1K	Buy	+17	New	+$1.2K	﹤0.01%	2579

Other funds holding AXSM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Parallel Advisors's AXSM Position: Q1 2026 in Review

Parallel Advisors increased its Axsome Therapeutics (AXSM) stake by 13% in Q1 2026, buying an estimated $345 and bringing the position to 17 shares worth $2.87K. The position accounts for ﹤0.01% of the portfolio, ranked #3249.

Parallel Advisors first reported a position in AXSM in Q1 2021 and has held it in 12 quarters since. The position peaked at $3K in Q4 2021. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

Parallel Advisors held 17 shares of Axsome Therapeutics worth $2.87K as of Q1 2026.
Parallel Advisors bought 2 Axsome Therapeutics shares in Q1 2026, an estimated $345.
Axsome Therapeutics made up ﹤0.01% of Parallel Advisors's portfolio in Q1 2026, its #3249 holding.
Parallel Advisors first reported a position in Axsome Therapeutics in Q1 2021 and has held it in 12 quarters since.
Parallel Advisors's Axsome Therapeutics position peaked at $3K in Q4 2021.
409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Parallel Advisors's 13F filing for Q1 2026, filed 7 May 2026.